Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fcγ/RIIIa-158 V/V and V/F polymorphism. Commenary

Saved in:
Bibliographic Details
Published inBlood Vol. 110; no. 7
Main Authors RODA, Julie M, BYRD, John C, MANNING, Robert J, LELEU, Xavier, DIMMOCK, Elizabeth A, KORTSARIS, Alexandros, MITSIADES, Constantine, ANDERSON, Kenneth C, FOX, Edward A, TREONL, Steven P, HATJIHARISSI, Evdoxia, LIAN XU, DITZEL SANTOS, Daniel, HUNTER, Zachary R, CICCARELLI, Bryan T, VERSELIS, Sigitas, MODICA, Michael, YANG CAO
Format Journal Article
LanguageEnglish
Published Washington, DC The Americain Society of Hematology 2007
Subjects
Antineoplastic agents
Biological and medical sciences
Hematologic and hematopoietic diseases
Immunotherapy
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
Pharmacology. Drug treatments
Antineoplastic agent
Human
Genetic variability
Rituximab
Genotype
Malignant hemopathy
Cellular immunity
Gene expression
Non Hodgkin lymphoma
Biological activity
Natural killer cell
Treatment
Lymphoproliferative syndrome
Immunotherapy
Antibody-dependent cell cytotoxicity
Anticytokine
Genetics
FcγRIII receptor
Lymphocyte
Cancer
Polymorphism
Online AccessGet full text

Cover

More Information
ISSN:0006-4971
1528-0020